MaxCyte, Inc. Notification of AGM and Audit Declaration (0594P)
October 08 2019 - 1:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 0594P
MaxCyte, Inc.
08 October 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notification of Annual General Meeting and Declaration of Audit
Remuneration
Gaithersburg, MD - 08 October 2019: MaxCyte (LSE: MXCT, MXCR),
the global cell-based medicines and life sciences company,
announces that formal notice and resolutions of the Company's
Annual General Meeting (AGM), have been circulated to
Shareholders.
These documents are also available in electronic form on the
Company's website: www.maxcyte.com.
In order to assist investors in considering the resolutions
proposed ahead of the AGM, the Company notes that the remuneration
of the Company's auditors, Cohn Rezhnick LLC, for audit-related
services relating to the 2018 financial year, amounted to
approximately $99,200.
The Annual General Meeting of Stockholders is planned to be held
at 11 a.m. EDT on 31 October 2019 at 21 Firstfield Road, Suite 202,
Gaithersburg, MD 20878, USA.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including six commercial
licenses. Aggregate potential pre-commercial milestones from all
license deals total more than $450m. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com.
###
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.
Chris Welsh com
Sukaina Virji
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAKDLFBKBFXFBK
(END) Dow Jones Newswires
October 08, 2019 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024